WO2026021940A1 - Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1 - Google Patents

Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1

Info

Publication number
WO2026021940A1
WO2026021940A1 PCT/EP2025/070143 EP2025070143W WO2026021940A1 WO 2026021940 A1 WO2026021940 A1 WO 2026021940A1 EP 2025070143 W EP2025070143 W EP 2025070143W WO 2026021940 A1 WO2026021940 A1 WO 2026021940A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
composition
skin
ranges
squalane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/070143
Other languages
English (en)
Inventor
Agustina GENTILE
Amanda Marie GOULSBRA
Michael John Hoptroff
Adrian John JERVIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2026021940A1 publication Critical patent/WO2026021940A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to topical skin care compositions with C16:1 fatty acid and their use for the maintenance or restoration of a healthy skin microbiome.
  • the skin is the body’s largest and most exposed organ system. Recent estimates of the epithelial surface area, accounting for hair follicles and sweat glands, suggest an expanse as large as 30m 2 . This vast region is densely populated with microorganisms that interact and compete to colonize and survive. These microorganisms, their combined genetic material, and the environment in which they live collectively form the human skin microbiome.
  • CoNS coagulase-negative Staphylococci
  • the skin of healthy individuals is colonized by a mixture of these CoNS, present at different ratios depending on whether the site is dry, moist, or sebaceous.
  • the most frequently isolated and best characterized CoNS from human skin is Staphylococcus epidermidis.
  • CoNS play a pivotal role in the orchestration of cutaneous homeostasis and immune competence. Studies show that CoNS can drive epidermal barrier development, educate, or tune the cutaneous immune response, and produce a variety of antimicrobial molecules to promote barrier function and integrity.
  • Dysregulation of these systems can disrupt the structure of the microbial community, a condition known as “dysbiosis”.
  • Dysbiosis refers to the lack of balance among microbial communities and is correlated with skin pathologies such as atopic dermatitis (AD).
  • Dysbiosis is also correlated with non-pathological conditions such as dry, oily, and aging skin.
  • Microbial dysbiosis in AD is characterized by a reduced microbial diversity, specifically manifested as a decrease in the genera Cutibacterium, Streptococcus, Acinetobacter, Corynebacterium and Prevotella, and a marked increase of Staphylococcus, especially of S. aureus.
  • the reduced microbial diversity is particularly evident during severe flares of the disease, with the reported composition of Staphylococcus usually reduced to a single S. aureus strain.
  • S. aureus The main intervention strategies used for the treatment of S. aureus involve topical antimicrobials and/or systemic antibiotics. Although such treatments are usually effective, they may also deplete or eliminate beneficial commensals such as Staphylococcus epidermidis and other CoNS. Hence, more targeted approaches are needed that aim to restore a healthy skin microbiome and promote the recovery of commensals.
  • C16 monounsaturated fatty acids such as 6-c/s-C16:1 (sapienic acid) possess a selective antibacterial activity against S. aureus.
  • Sapienic acid which is present in human sebum, is considered to control the skin microbiota as a natural antimicrobial agent. Indeed, the level of sapienic acid is lower in atopic dermatitis patients than in healthy individuals and is inversely correlated to the abundance of S. aureus.
  • the present inventors have found that enhanced efficacy against S. aureus can be obtained when C16:1 fatty acids such as sapienic acid are combined with certain actives.
  • the invention provides a topical skin care composition comprising:
  • the invention also provides a cosmetic, non-therapeutic method for balancing the relative abundance of Staphylococcus strains within the skin microbiome, the method comprising the step of topically applying the composition as described above to the skin.
  • the invention also provides the cosmetic, non-therapeutic use of the composition as described above for balancing the relative abundance of Staphylococcus strains within the skin microbiome.
  • the invention also provides the composition as described above for use in the treatment of skin pathologies associated with S. aureus overgrowth, such as atopic dermatitis (AD).
  • AD atopic dermatitis
  • topical application means to apply the skin care composition onto the surface of the skin.
  • C16:1 fatty acid refers to a fatty acid with a hydrocarbyl chain having 16 carbon atoms and one carbon-carbon double bond.
  • the C16:1 fatty acid may be used in the free acid form or in the form of a derivative such as a salt or ester.
  • salts or esters include ammonium, sodium, potassium, magnesium, or calcium salts, lower (Ci_ 4 ) alkyl esters (e.g. methyl or ethyl esters), and mono-, di- or triglycerides.
  • the C16:1 fatty acid is used in the free acid form.
  • the C16:1 fatty acid may suitably correspond to general formula (I):
  • m ranges from 4 to 9.
  • the double bond is of the Z-configuration
  • C16:1 fatty acids of general formula (I) for use in compositions of the invention include (Z)-hexadec-6-enoic acid (also termed 16:1n-7O or sapienic acid), (Z)- hexadec-7-enoic acid (also termed 16:1n-9 or hypogeic acid) and (Z)-hexadec-9-enoic acid (also termed 16:1n-7 or palmitoleic acid).
  • Sources of these materials include marine oils, microbial ferments, and botanical oils such as macadamia (Macadamia integrifolia) nut oil, sea buckthorn (Hippophae rhamnoides) pulp oil and Thunbergia alata seed oil.
  • Sapienic acid and hypogeic acid are particularly preferred for use in compositions of the invention, in view of their higher selectivity towards S. aureus than palmitoleic acid.
  • Sapienic acid and hypogeic acid each have an antimicrobial activity against S. aureus which is over 100- fold higher than that for S. epidermidis. Sapienic acid is most preferred since this has the highest antimicrobial activity whilst also demonstrating selectivity against S. aureus. Mixtures of any of the above-described materials may also be used.
  • composition of the invention will typically contain from about 0.01 to about 5%, such as about 0.1 to 2% (by weight based on the total weight of the composition) of C16:1 fatty acid.
  • composition of the invention will preferably contain from about 0.01 to about 5%, such as about 0.1 to 2% (by weight based on the total weight of the composition) of total C16:1 fatty acid and from about 0.01 to about 5%, such as about 0.1 to 2% (by weight based on the total weight of the composition) of sapienic acid, hypogeic acid and palmitoleic acid or a mixture thereof.
  • composition of the invention will more preferably contain from about 0.01 to about 5%, such as about 0.1 to 2% (by weight based on the total weight of the composition) of total C16:1 fatty acid, and from about 0.01 to about 5%, such as about 0.1 to 2% (by weight based on the total weight of the composition) of sapienic acid.
  • Squalane is a linear saturated hydrocarbon corresponding to general formula (II):
  • Squalane may be produced by hydrogenating squalene extracted from vegetable sources such as olive oil milling residues; or derived from sugar cane sucrose fermentation using the non- pathogenic yeast Saccharomyces cerevisiae. This fermentation results in the sesquiterpene frans-jB-farnesene, which is dimerized and subsequently hydrogenated in situ to squalane.
  • composition of the invention will typically contain from about 0.01 to about 5% and preferably contains from about 0.1 to 2% of squalane (by weight based on the total weight of the composition).
  • the weight ratio of C16:1 fatty acid to squalane typically ranges from about 5:1 to about 1 :5, preferably from about 3:1 to about 1 :3 and most preferably about 1.5:1 to about 1 :1.5.
  • the weight ratio of total C16:1 fatty acid to squalane ranges from about 5:1 to about 1 :5, preferably from about 3:1 to about 1 :3 and most preferably about 1 .5:1 to about 1 :1.5
  • the weight ratio of sapienic acid, hypogeic acid and palmitoleic acid or a mixture thereof to squalane ranges from about 5: 1 to about 1 :5, preferably from about 3:1 to about 1 :3 and most preferably about 1 .5:1 to about 1 :1.5.
  • the weight ratio of total C16:1 fatty acid to squalane ranges from about 5:1 to about 1 :5, preferably from about 3:1 to about 1 :3 and most preferably about 1 .5:1 to about 1 :1.5 and the weight ratio of sapienic acid to squalane ranges from about 5:1 to about 1 :5, preferably from about 3:1 to about 1 :3 and most preferably about 1.5:1 to about 1 :1.5.
  • Topical skin care compositions of the invention are preferably cosmetic compositions.
  • cosmetic compositions denotes compositions which are used to regulate and/or improve cosmetic qualities of the skin (as opposed to curing, treating, or preventing a disease or disorder). Such cosmetic qualities are subject to regulation and/or improvement both in healthy subjects as well as those which present diseases or disorders of the skin (such as psoriasis, lichen planus, folliculitis, or atopic dermatitis).
  • Examples of regulating and/or improving cosmetic qualities of the skin include reducing skin malodour, providing a smoother, more even skin texture; improving the hydration status or moisturization of the skin; improving skin barrier properties; reducing skin sensitivity and reducing the appearance of redness or skin blotches.
  • compositions of the invention can be formulated in a variety of forms for topical application and will generally include a cosmetically acceptable vehicle.
  • Cosmetically acceptable means that the vehicle is suitable for topical application to the skin, has good aesthetic properties, is compatible with the other ingredients, and will not cause any safety or toxicity concerns.
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase, or a mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams, and heavy creams.
  • Exemplary emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, polyol-in-silicone emulsions, silicone-in-polyol emulsions, polyol-in-oil emulsions, oil-in-polyol emulsions, wax-in-water emulsions, and water- oil-water triple emulsions.
  • Preferred emulsions include oil-in-water emulsions and water-in-oil emulsions.
  • Topical skin care compositions of the invention which are in the form of an emulsion typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
  • Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of glycols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl oleate
  • Topical skin care compositions of the invention which are in the form of an emulsion typically have an aqueous phase, with the amount of water in such an emulsion suitably ranging from about 5 to about 95%, preferably from about 35 to about 80% (by weight based on the total weight of the composition).
  • the aqueous phase may also include one or more organic liquids that are miscible with water at room temperature (25°C).
  • Exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C 2 -C 6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C 3 -Ci 6 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
  • C 2 -C 6 alkanols such as ethanol and isopropanol
  • C2-C10 glycols and polyols such as glycerol, propylene glycol, butylene glyco
  • Topical skin care compositions of the invention which are in the form of an emulsion generally include emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
  • the amount of emulsifier and solubilizer in such an emulsion suitably ranges from about 0.1 to about 30%, preferably from about 1 to about 8% (by weight based on the total weight of the composition).
  • Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, cetyl phosphate, diethanol
  • Topical skin care compositions of the invention may also take the form of a skin cleanser incorporating one or more cleansing surfactants which, when combined with water and mechanically agitated, generate a foam or lather.
  • the amount of cleansing surfactant suitably ranges from about 5 to about 40%, preferably from about 10 to about 35% (by weight based on the total weight of the composition).
  • Exemplary cleansing surfactants include anionic surfactants such as ammonium lauroyl sarcosinate, sodium trideceth sulfate, sodium lauroyl sarcosinate, sodium myristoyl sarcosinate, ammonium laureth sulfate, sodium laureth sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium cocoyl glycinate, sodium lauroyl glycinate, sodium lauroyl taurate, sodium methyl lauroyl taurate, sodium methyl oleoyl taurate, sodium cetyl sulfate, sodium lauroyl lactylate and triethanolamine lauroyl lactylate and mixtures thereof; nonionic surfactants such as lauramine oxide, cocoamine oxide, decyl polyglucose,
  • Topical skin care compositions of the invention may also be formulated in a single-phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • a single-phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • Topical skin care compositions of the invention may also be formulated in solid forms such as gels or sticks.
  • Topical skin care compositions of the invention may include additional skin care actives (for improving the physical and/or aesthetic characteristics of the skin).
  • additional skin care actives which are suitable for use in the invention include vitamins, minerals and/or antioxidants, emollients, humectants, skin anti-hyperpigmentation agents, sunscreens, antiirritants, exfoliating agents, and mixtures thereof.
  • Vitamins, minerals and/or antioxidants suitable for use in compositions of the invention include natural botanical antioxidants derived from plant materials such as fruits, vegetables, herbs and spices (such as goji berry, white tea, rosemary, green tea, grape seed and lemongrass extracts); vitamin A and its precursors or derivatives (such as beta-carotene, retinyl palmitate); vitamin B5 and its precursors or derivatives (such as panthenol and its precursors or derivatives); vitamin C and its precursors or derivatives (such as tetrahexyldecyl ascorbate, ascorbyl palmitate); vitamin E and its precursors or derivatives (such as d-alpha-tocopherol, tocopheryl acetate); vitamin K and its precursors or derivatives; selenium and its derivatives (such as L-selenomethionine); and alpha lipoic acid.
  • natural botanical antioxidants derived from plant materials such as fruits, vegetables, herbs and spices (such as goji berry, white tea, rosemary,
  • Emollients suitable for use in compositions of the invention act to increase and maintain moisture in the skin by providing a protective coating to impede epidermal water loss.
  • emollients include C10-20 fatty alcohols and acids (such as cetyl, myristyl, palmitic and stearyl alcohols and acids); and C10-40 hydrocarbons (such as mineral oil, petroleum jelly, squalene and isoparaffins).
  • Humectants suitable for use in compositions of the invention act to increase and maintain moisture in the skin by attracting water to the stratum corneum of the epidermis.
  • humectants include amino acids, chondroitin sulfate, glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1 ,3-butylene glycol, 1 ,4- butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, erythritol, fructose, glucose, maltose, sucrose, lactose, xylose, inositol, lactitol, xylitol, sorbitol, mannitol, maltitol, pantheno
  • Skin anti-hyperpigmentation agents suitable for use in compositions of the invention include natural botanical agents derived from plant materials (such as Arctostaphylos patula and Arctostaphylos viscida extracts, Emblica officinalis extract, Mitracarpus scaber extract, Uva ursi (bearberry) extract, Morus bombycis (mulberry) extract, Morus alba (white mulberry) extract, Broussonetia papyrifera (paper mulberry) extract, licorice extract, acerola cherry extract, Chlorella vulgaris extract, Aloe ferrox extract and Rumex occidentalis extract); synthetic or natural sugar amines (such as glucosamine, N-acetyl glucosamine, glucosamine sulfate, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine and their hydrochloride salts); retinoids (such as retinol, retina
  • Sunscreens suitable for use in compositions of the invention protect the skin from ultraviolet (UV) solar radiation falling within both the UVB region (between 290nm to 320 nm wavelengths) and the UVA region (between 320nm and 400nm wavelengths).
  • sunscreens include methoxycinnamate derivatives (such as octyl methoxycinnamate and isoamyl methoxycinnamate); camphor derivatives (such as 4-methyl benzylidene camphor, camphor benzalkonium methosulfate, and terephthalylidene dicamphor sulfonic acid); salicylate derivatives (such as octyl salicylate and homosalate); sulfonic acid derivatives (such as phenylbenzimidazole sulfonic acid); benzone derivatives (such as dioxybenzone, sulisobenzone, and oxybenzone); benzoic acid derivatives (such as aminobenzoic acid and oct
  • Anti-irritants suitable for use in compositions of the invention include allantoin, aloe vera, a- bisabolol, caffeine, chamomile extract, Cola nitada extract, cucumber extract, dipotassium glycyrrhizinate, glycyrrhizic acid, green tea extract, lecithin or hydrogenated lecithin, licorice extract, Avena sativa (oat) meal extract, tea tree oil, salicylic acid, acetylsalicylic acid, strontium acetate, strontium chloride, strontium nitrate, fatty acids with anti-irritant properties (such as linoleic acid and linolenic acid) and aromatic aldehydes with anti-irritant properties (such as 4- methoxy benzaldehyde, 4-ethoxy benzaldehyde, 4-butoxy benzaldehyde and 4-pentoxy benzaldehyde).
  • Exfoliating agents suitable for use in compositions of the invention include benzoyl peroxide, benzoic acid, 3-hydroxy benzoic acid, salicylic acid, acetic acid, trichloroacetic acid, 1- pyrrolidone-5-carboxylic acid, a-hydroxy acids (such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid); p-hydroxy acids (such as p-hydroxybutyric acid); a-keto acids (such as pyruvic acid, 2-oxopropanoic acid, 2-oxobutanoic acid and 2-oxopentanoic acid); and oxa acids (such as 3,6,9-trioxaundecanedioic acid).
  • a-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid
  • p-hydroxy acids such as p-hydroxybutyric acid
  • a-keto acids such as pyruvic acid, 2-oxo
  • Topical skin care compositions of the invention may include additional functional ingredients (for improving the physical and/or aesthetic characteristics of the composition).
  • water soluble or colloidally water soluble polymeric thickening agents such as hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, cross-linked polyacrylate polymers and polyacrylamide polymers
  • structurant clays such as magnesium aluminum silicate, attapulgite, bentonite, montmorillonite and hectorite
  • inorganic pigments such as titanium oxide, zirconium oxide, cerium oxide zinc oxide, iron oxide, chromium oxide and ferric blue
  • organic pigments such as carbon black and barium, strontium, calcium, and aluminium lakes
  • pearlescent agents such as mica coated with titanium oxide and/or iron oxide
  • the above-described topical skin care composition of the invention may be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or a cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • composition is suitably applied to the skin at the rate of one or two applications per day.
  • an amount corresponding to about 1 to 2 ml of the composition per application is applied uniformly over the area of treatment twice daily for a period of at least 7 (seven) days, more preferably at least 30 (thirty) days.
  • the invention will be further illustrated by the following, non-limiting Examples.
  • MIC Minimum Inhibitory Concentration
  • MIC is defined as the absolute lowest concentration of active that provides complete microbial growth inhibition as indicated by the colour change of Alamar blue under the tested conditions.
  • test actives 5% (w/v) stock solutions of test actives were prepared with DMSO. 200pL of stock solution was dispensed into the first column of 96 well plates. 100pL from column 1 was serially diluted down to column 10 in 100pL sterile distilled water. Bacterial cultures were prepared at a titre of 1x10 8 CFU/mL and following a 150x dilution into the corresponding growth medium, 100pL of bacteria/medium mix was added to test wells. The plates were inoculated at 37°C for 24 hours. Plates were visually checked to determine the visual MIC alongside an absorbance reading of 620nm taken before and after incubation to confirm the results. Growth was indicated by Alamar blue used at a concentration of 10% well volume. MIC was determined as the lowest concentration with a fluorescence value that matches or close to the fluorescence value of the negative control. This was obtained following incubation by subtracting the 0-hour read from the post-incubation read (24 hours).
  • Positive control 10OpL of bacteria/medium mix and 10OpL of sterile distilled water
  • Negative control 100pL of sterile medium and 100pL of sterile distilled water.
  • DMSO control To assess the specific impact of DMSO on the viability of tested bacteria, DMSO diluted to 50% in sterile distilled water was used to match the DMSO concentrations used for solubilising the test actives. The results are shown in the following Table 1 :

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition topique pour le soin de la peau comprenant : (i) de 0,01 à 10 % en poids (en poids par rapport au poids total de la composition) d'un ou de plusieurs acides gras en C16:1, et (ii) de 0,01 à 10 % en poids (en poids sur la base du poids total de la composition) de squalane ; le rapport en poids entre (i) et (ii) variant de 10 : 1 à 1 : 10. La composition de l'invention présente une efficacité améliorée contre S aureus et peut être utilisée pour le maintien ou la restauration d'un microbiome cutané sain.
PCT/EP2025/070143 2024-07-23 2025-07-14 Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1 Pending WO2026021940A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24190488.7 2024-07-23
EP24190488 2024-07-23

Publications (1)

Publication Number Publication Date
WO2026021940A1 true WO2026021940A1 (fr) 2026-01-29

Family

ID=91969286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/070143 Pending WO2026021940A1 (fr) 2024-07-23 2025-07-14 Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1

Country Status (1)

Country Link
WO (1) WO2026021940A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0977653A (ja) * 1995-09-14 1997-03-25 Advance Co Ltd 化粧料
JP4776058B2 (ja) * 1999-10-06 2011-09-21 サンスター株式会社 皮膚改善剤
CN105733862A (zh) * 2016-03-01 2016-07-06 苏州市贝克生物科技有限公司 洁面皂及其制备方法
CN116370326A (zh) * 2022-03-25 2023-07-04 威娜德国有限责任公司 用于增强角蛋白纤维的组合物
US20230383320A1 (en) * 2022-05-27 2023-11-30 Shizuoka Prefectural University Corporation Method for producing monounsaturated fatty acid having 16 carbon atoms
WO2024014801A1 (fr) * 2022-07-12 2024-01-18 전종열 Procédé de préparation d'acide sapiénique, d'un isomère trans de celui-ci et d'ester d'acide sapiénique
KR20240061133A (ko) * 2022-10-31 2024-05-08 전종열 화장품, 생활용품 및 손 세정제용 항균 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0977653A (ja) * 1995-09-14 1997-03-25 Advance Co Ltd 化粧料
JP4776058B2 (ja) * 1999-10-06 2011-09-21 サンスター株式会社 皮膚改善剤
CN105733862A (zh) * 2016-03-01 2016-07-06 苏州市贝克生物科技有限公司 洁面皂及其制备方法
CN116370326A (zh) * 2022-03-25 2023-07-04 威娜德国有限责任公司 用于增强角蛋白纤维的组合物
US20230383320A1 (en) * 2022-05-27 2023-11-30 Shizuoka Prefectural University Corporation Method for producing monounsaturated fatty acid having 16 carbon atoms
WO2024014801A1 (fr) * 2022-07-12 2024-01-18 전종열 Procédé de préparation d'acide sapiénique, d'un isomère trans de celui-ci et d'ester d'acide sapiénique
KR20240061133A (ko) * 2022-10-31 2024-05-08 전종열 화장품, 생활용품 및 손 세정제용 항균 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubmed [online] 1 March 2013 (2013-03-01), WOLOSIK KATARZYNA ET AL: "The importance and perspective of plant-based squalene in cosmetology - PubMed", XP093238249, retrieved from https://pubmed.ncbi.nlm.nih.gov/23449131/ Database accession no. 23449131 *

Similar Documents

Publication Publication Date Title
US11833242B2 (en) Skin care formulations
EP2355793B1 (fr) Compositions antioxydantes pour la purification et le conditionnement de la peau
KR20130049729A (ko) 상승적으로 작용하는 3원 항미생물 혼합물
EP4218712A1 (fr) Utilisation d'une composition topique de soins de la peau d'enrichissement sélectif de microbes commensaux dermiques résidents
CA2741671C (fr) Compositions topiques contenant du cis-6-nonenol et ses derives et procedes de traitement de la peau
WO2026021940A1 (fr) Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1
WO2026022038A1 (fr) Compositions topiques pour le soin de la peau comprenant un acide gras en c16:1
WO2026022035A1 (fr) Compositions topiques de soins de la peau comprenant un acide gras en c16:1
WO2026021941A1 (fr) Compositions topiques de soins de la peau comprenant un acide gras en c16:1
US12396936B2 (en) Antimicrobial composition for tackling malodour
WO2025012295A1 (fr) Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci
FR2921558A1 (fr) Composition antimicrobienne utilisable en cosmetique et en dermatologie.
WO2025021434A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2024223320A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
EP4701614A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
EP4701740A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2025252619A1 (fr) Méthodes cosmétiques pour soins de la peau
WO2025113965A1 (fr) Utilisation de l-aspartate pour améliorer la production de pantothénate
EP4218713A1 (fr) Utilisation d'une composition topique de soins de la peau pour améliorer la biosynthèse des lipides de la couche cornée
WO2025114095A1 (fr) Utilisation de l-valine pour augmenter la biosynthèse de nicotinamide riboside
US20250049679A1 (en) Formulations of eriodictyol
WO2022184763A1 (fr) Utilisation de galacto-oligosaccharides pour procurer des bienfaits à la peau
WO2025114094A1 (fr) Utilisation de l-aspartate
WO2026052309A1 (fr) Composition cosmétique à base d'acétyl méthionine et d'ubiquinone
WO2026052310A1 (fr) Composition cosmétique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25741127

Country of ref document: EP

Kind code of ref document: A1